Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Genome-wide screen overexpressing mycobacteriophage Amelie genes identifies multiple inhibitors of mycobacterial growth.
G3 (Bethesda)
December 2024
Department of Biology, La Sierra University, Riverside, California, 92503, USA.
The genome sequences of thousands of bacteriophages have been determined and functions for many of the encoded genes have been assigned based on homology to characterized sequences. However, functions have not been assigned to more than two-thirds of the identified phage genes as they have no recognizable sequence features. Recent genome-wide overexpression screens have begun to identify bacteriophage genes that encode proteins that reduce or inhibit bacterial growth.
View Article and Find Full Text PDFComparative study on the virulence of mycobacteriophages.
bioRxiv
October 2024
Department of Chemical and Materials Engineering, University of Alberta, Edmonton, Alberta, Canada.
The global tuberculosis (TB) epidemic affected 10 million people and caused 1.3 million deaths in 2022 alone. Multidrug-resistant TB is successfully treated in less than 60% of cases by long, expensive and aggressive treatments.
View Article and Find Full Text PDFMycobacteriophages and Their Applications.
Antibiotics (Basel)
September 2024
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, 56126 Pisa, Italy.
Mycobacterial infections caused by tuberculous and non-tuberculous strains pose significant treatment challenges, especially among immunocompromised patients. Conventional antibiotic therapies often fail due to bacterial resistance, highlighting the need for alternative therapeutic strategies. Mycobacteriophages are emerging as promising candidates for the treatment of mycobacteria.
View Article and Find Full Text PDFEngineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates.
J Infect Dis
October 2024
Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Background: Drug-resistant tuberculosis is a growing public health threat, and early characterization of the resistance phenotype is essential for guiding treatment and mitigating the high mortality associated with the disease. However, the slow growth rate of Mycobacterium tuberculosis, the causative agent of tuberculosis, necessitates several weeks for conventional culture-dependent drug susceptibility testing (DST). In addition, there are no widely available molecular diagnostic assays for evaluating resistance to newer tuberculosis drugs or drugs with complex resistance mechanisms.
View Article and Find Full Text PDFFluorescent lateral flow assay strip for Mycobacterium tuberculosis and Mycobacterium smegmatis based on mycobacteriophage tail protein and aptamer.
Talanta
January 2025
Key Laboratory of Luminescence Analysis and Molecular Sensing (Ministry of Education), College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China. Electronic address:
Article Synopsis
- Timely detection of Mycobacterium tuberculosis (M. tuberculosis) is crucial for controlling tuberculosis, and Mycobacterium smegmatis (M. smegmatis) is often used for research in its place.
- A tail protein called GP89, derived from a mycobacteriophage, acts as a binding agent on a lateral flow assay (LFA) strip, enabling quick detection of both M. tuberculosis and M. smegmatis.
- The GP89-based LFA can detect these bacteria in samples like urine and saliva within 10 minutes, making it a valuable tool for diagnosing tuberculosis in low-resource settings, with specific detection limits of 2.0 CFU/mL for M. tuberculosis and
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!